Medical network - February 17 in chicken is said to be the year. But for the pharmaceutical industry practitioners, chicken years no like of doors. In monkey chicken intersection, wave after wave of government action, already let the medical industry shocks.
The end of year of the monkey, can be summarized as the strengthening of the supply side administrative controls; The chicken in the early years of government action, can be expected to demand side payment mode of updates.
Administrative controls to strengthen, the sword refers to hospital on drug distribution both behavior. New orders, including drug zero rate, two votes and strict reorganization of the wind of kickbacks.
Pay the model update, sword refers to a hospital in the medical service provides both the incentive mechanism. This update, dominated by the government through a series of New Deal to implement health care institutions, including health care medicine, health care drugs the update payment standard establishment and medical insurance payment system reform.
However, due to the information and motivation problems, regulators and validity of the control will decline with the passage of time.
Update payment mode, however, otherwise, it involves the relationship between the buyer and the supplier purchase reconstruction, which can rebuild the incentive mechanism of medical supply side, alter the behavior of the supplier. Compared with a series of control measures in the town, health care medicine for medicine industry upstream and downstream of the shock of the New Deal, will be more intense, more durable.
Health care medicine New Deal the first line of shock waves, and to before and after will be two sessions in 2017. This is the medicine of insurance of primary medical treatment to pay standard rules.
Medicare drug payment standard, in fact, as early as the early summer of 2015 on the agenda for the government. At that time, the national development and reform commission under the impact of the tide of anti-corruption, launched the drug pricing reform policies, its core content are two: one is to abolish the national development and reform commission, the drugs, the highest retail price system; The second is to promote health care institutions and medical institutions and pharmaceutical companies to determine the price of drugs through negotiation, the medicare drug payment standard. Thus, health care institutions from passive executors of drug price policy for pharmaceuticals price makers.
Authorities in charge of health care institutions, however, change the role, spent a year and a half, roughly three reasons: (1) the integration of urban and rural health care after years of delays until the end of year of the monkey dust settles; (2) health care medicine at the end of the year of the monkey to complete the update; (3) pay medicare drug standard details of the new rules more controversial.
Medicare drug payment standard the content of the New Deal a lot, but most importantly, regardless of the pay standards shall be formulated by the health care institutions for which level of government, also, no matter how much pay standard of medical institutions shall have the right to conduct negotiations with pharmaceutical companies for drug purchase price, and the difference between the purchase price and pay the price, shall be owned by the medical institution.
This means that the medical institutions drug distribution model will be a substantial change, they only purchasing drugs in the form of the highest cost performance, in order to maximize their own interests. As a result, all kinds of medical institutions may organize, (GPO) in the form of a variety of group purchase, negotiate with pharmaceutical companies to carry out the drug prices. The phenomenon of drug prices artificially high, will gradually fade, the drug centralized bidding system also suffer.
Medicare drug "New Deal" shock wave transmission to the upper reaches of the pharmaceutical enterprises. In the face of the change of medical institutions and drug procurement behavior, pharmaceutical enterprise market restructuring is hindering. Medical supply side and demand side of structural reforms that will resonate in the pharmaceutical industry. |
